穿孔素1(PRF1)活性蛋白
Active Perforin 1 (PRF1)
FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein
- 編號APB317Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 80%
- 等電點7.7
- 應用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1800 ¥ 4500 ¥ 9000 ¥ 27000 ¥ 67500
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
活性實驗
Figure. The binding activity of PRF1 with CRT.
Perforin 1 (PRF1) is a pore forming cytolytic protein found in the granules of cytotoxic T lymphocytes (CTLs) and NK cells. Upon degranulation, perforin binds to the target cell's plasma membrane, and oligomerises in a Ca2 dependent manner to form pores on the target cell. The pore formed allows for the passive diffusion of a family of pro-apoptotic proteases, known as the granzymes, into the target cell. Besides, Calreticulin (CRT) has been identified as an interactor of PRF1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PRF1 and recombinant human CRT. Briefly, PRF1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to CRT-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PRF1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of PRF1 and CRT was shown in Figure 1, and this effect was in a dose dependent manner.
Figure. Hemolysis activity of recombinant human PRF1.
The activity of recombinant PRF1 was measured by lysis of erythrocytes using a hemolysis assay. A general procedure is as fllows: two-fold dilute the recombinant human PRF1 with 0.9% NaCl, add 50μL a serial dilution of PRF1, 10μL 0.1M CaCl2 to each well, then add 50μL 0.25% rabbit erythrocyte (RaE) to each well and mixed gently. Add 10μL 0.9% NaCl to reaplace CaCl2 in control wells. The plate is incubated for 20 hours at 37℃, 5% CO2. The results are shown in Figure 2. It was obvious that the minimal effective concentration of PRF1 is 12.5μg/mL.
(A) 0.25% RaE tread with 12.5μg/mL PRF1 for 20h;
(B) Negative control (0.25% RaE tread with 12.5ug/mL PRF1) without CaCl2.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
增值服務
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
RPB317Hu02 | 穿孔素1(PRF1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB317Hu01 | 穿孔素1(PRF1)活性蛋白 | Cell?culture;?Activity?Assays. |
RPB317Hu01 | 穿孔素1(PRF1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB317Hu02 | 穿孔素1(PRF1)活性蛋白 | Cell?culture;?Activity?Assays. |
PAB317Hu01 | 穿孔素1(PRF1)多克隆抗體 | WB; IHC; ICC; IP. |
LAB317Hu81 | 穿孔素1(PRF1)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
LAB317Hu71 | 穿孔素1(PRF1)多克隆抗體(生物素標記) | WB; IHC; ICC. |
MAB317Hu22 | 穿孔素1(PRF1)單克隆抗體 | WB; IHC; ICC; IP. |
MAB317Hu21 | 穿孔素1(PRF1)單克隆抗體 | WB; IHC; ICC; IP. |
SEB317Hu | 穿孔素1(PRF1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB317Hu | 穿孔素1(PRF1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Diagnostic Microbiology and Infectious Disease | Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection [Pubmed:26915636] |
FASEB?JOURNAL | The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis [Pubmed: 30951375] |
Theranostics | A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors [Pubmed: 31695790] |
Mol Immunol | CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection [Pubmed: 33223223] |
INVESTIGATIONAL NEW DRUGS | Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors [Pubmed: 32772342] |
Am J Transl Res | Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma [34377237] |
Nat Biomed Eng | Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy [34873307] |
J Exp Med | Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion [Pubmed:35061012] |